Abstract

It is well established that antibiotic treatment selects for resistance, but the dynamics of this process during infections are poorly understood. Here we map the responses of Pseudomonas aeruginosa to treatment in high definition during a lung infection of a single ICU patient. Host immunity and antibiotic therapy with meropenem suppressed P. aeruginosa, but a second wave of infection emerged due to the growth of oprD and wbpM meropenem resistant mutants that evolved in situ. Selection then led to a loss of resistance by decreasing the prevalence of low fitness oprD mutants, increasing the frequency of high fitness mutants lacking the MexAB-OprM efflux pump, and decreasing the copy number of a multidrug resistance plasmid. Ultimately, host immunity suppressed wbpM mutants with high meropenem resistance and fitness. Our study highlights how natural selection and host immunity interact to drive both the rapid rise, and fall, of resistance during infection.

Here, following a patient with severe acute Pseudomonas aeruginosa infection, the authors combine comprehensive isolate characterization from lung and gut samples (>100 isolates) and patient clinical data to provide insights into bacterial responses to antibiotic therapy.

Details

Title
Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection
Author
Wheatley, Rachel 1   VIAFID ORCID Logo  ; Diaz Caballero Julio 1 ; Kapel Natalia 1 ; de Winter Fien H R 2   VIAFID ORCID Logo  ; Jangir Pramod 1 ; Quinn, Angus 1   VIAFID ORCID Logo  ; del Barrio-Tofiño Ester 3 ; López-Causapé, Carla 3 ; Hedge, Jessica 1   VIAFID ORCID Logo  ; Torrens, Gabriel 3 ; Van der Schalk Thomas 2   VIAFID ORCID Logo  ; Britto, Xavier Basil 2   VIAFID ORCID Logo  ; Fernández-Cuenca, Felipe 4 ; Arenzana Angel 4 ; Recanatini Claudia 5   VIAFID ORCID Logo  ; Timbermont Leen 2   VIAFID ORCID Logo  ; Sifakis Frangiscos 6 ; Ruzin Alexey 7 ; Ali, Omar 8 ; Lammens, Christine 2 ; Goossens, Herman 2 ; Kluytmans Jan 9 ; Kumar-Singh, Samir 10 ; Oliver, Antonio 3 ; Malhotra-Kumar Surbhi 2   VIAFID ORCID Logo  ; MacLean, Craig 1   VIAFID ORCID Logo 

 University of Oxford, Department of Zoology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Vaccine and Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681) 
 Hospital Universitario Son Espases, Palma de Mallorca, Spain (GRID:grid.411164.7) (ISNI:0000 0004 1796 5984) 
 Universidad de Sevilla, Departamento de Medicina, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229) 
 University Medical Center Utrecht, Utrecht University, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352) 
 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717) 
 Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA (GRID:grid.418152.b) 
 Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA (GRID:grid.418152.b); Viela Bio, Gaithersburg, USA (GRID:grid.418152.b) 
 University Medical Center Utrecht, Utrecht University, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Microvida Laboratory for Medical Microbiology and Department of Infection Control, Amphia Hospital, Breda, The Netherlands (GRID:grid.413711.1) 
10  Vaccine and Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681); University of Antwerp, Molecular Pathology Group, Faculty of Medicine—Laboratory of Cell Biology and Histology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2519143443
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.